PT4065585T - Compostos macrocíclicos substituídos e métodos de tratamento relacionados - Google Patents
Compostos macrocíclicos substituídos e métodos de tratamento relacionadosInfo
- Publication number
- PT4065585T PT4065585T PT208284638T PT20828463T PT4065585T PT 4065585 T PT4065585 T PT 4065585T PT 208284638 T PT208284638 T PT 208284638T PT 20828463 T PT20828463 T PT 20828463T PT 4065585 T PT4065585 T PT 4065585T
- Authority
- PT
- Portugal
- Prior art keywords
- treatment
- related methods
- macrocyclic compounds
- substituted macrocyclic
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962939825P | 2019-11-25 | 2019-11-25 | |
| US202063030979P | 2020-05-28 | 2020-05-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT4065585T true PT4065585T (pt) | 2025-09-30 |
Family
ID=73856348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT208284638T PT4065585T (pt) | 2019-11-25 | 2020-11-25 | Compostos macrocíclicos substituídos e métodos de tratamento relacionados |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US11542276B2 (pt) |
| EP (2) | EP4628167A3 (pt) |
| JP (2) | JP7787812B2 (pt) |
| KR (2) | KR20260083444A (pt) |
| CN (1) | CN114761412B (pt) |
| AU (2) | AU2020394444B2 (pt) |
| BR (1) | BR112022009938A2 (pt) |
| DK (1) | DK4065585T3 (pt) |
| ES (1) | ES3041424T3 (pt) |
| FI (1) | FI4065585T3 (pt) |
| HR (1) | HRP20251156T1 (pt) |
| HU (1) | HUE073461T2 (pt) |
| IL (2) | IL293240B2 (pt) |
| LT (1) | LT4065585T (pt) |
| MA (1) | MA57908B1 (pt) |
| MD (1) | MD4065585T2 (pt) |
| MX (1) | MX2022006206A (pt) |
| PT (1) | PT4065585T (pt) |
| RS (1) | RS67202B1 (pt) |
| SA (1) | SA522432691B1 (pt) |
| SI (1) | SI4065585T1 (pt) |
| SM (1) | SMT202500340T1 (pt) |
| WO (1) | WO2021108628A1 (pt) |
| ZA (1) | ZA202206482B (pt) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20260083444A (ko) | 2019-11-25 | 2026-06-05 | 알케르메스,인코포레이티드 | 치환된 마크로사이클릭 화합물 및 관련 치료 방법 |
| US12503475B2 (en) | 2020-09-03 | 2025-12-23 | Centessa Pharmaceuticals (Uk) Limited | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists |
| CN116635393A (zh) * | 2020-09-03 | 2023-08-22 | 欧瑞夏治疗有限公司 | 中环或大环苄基取代的杂环衍生物及其作为食欲素-2受体激动剂的用途 |
| EP4247801A4 (en) * | 2020-11-23 | 2024-10-30 | Merck Sharp & Dohme LLC | 3-AMINO PYRROLIDINE AND MACROCYCLIC PIPERIDINE OREXIN RECEPTOR AGONISTS |
| US12006330B2 (en) | 2020-12-21 | 2024-06-11 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| WO2022207935A1 (en) | 2021-04-02 | 2022-10-06 | Orexia Therapeutics Limited | 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists |
| WO2022232025A1 (en) * | 2021-04-26 | 2022-11-03 | Alkermes, Inc. | Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity |
| AU2022281345A1 (en) * | 2021-05-26 | 2023-11-30 | Alkermes, Inc. | Substituted fused bicyclic macrocyclic compounds and related methods of treatment |
| JP7833486B2 (ja) * | 2021-05-26 | 2026-03-19 | アルカーメス，インコーポレイテッド | 置換されるカルバメート大環状化合物および関連のある治療方法 |
| WO2023167925A1 (en) * | 2022-03-01 | 2023-09-07 | Orexia Therapeutics Limited | Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and related uses |
| TW202432109A (zh) | 2022-10-31 | 2024-08-16 | 日商武田藥品工業股份有限公司 | 食慾素２型受體促效劑之給藥 |
| CN120584118A (zh) * | 2022-11-23 | 2025-09-02 | 沃泰克斯药物股份有限公司 | 食欲素受体2的经取代的大环胺调节剂 |
| JPWO2024128305A1 (pt) | 2022-12-16 | 2024-06-20 | ||
| JP2026506356A (ja) | 2023-01-31 | 2026-02-24 | ジャズ ファーマシューティカルズ アイルランド リミテッド | 大環状オレキシン受容体アゴニスト及びその使用 |
| EP4680611A1 (en) | 2023-03-16 | 2026-01-21 | Takeda Pharmaceutical Company Limited | Macrocyclic heterocycle compounds and use thereof |
| JP2026518313A (ja) * | 2023-06-01 | 2026-06-04 | ハー・ルンドベック・アクチエゼルスカベット | スピロ大環状オレキシン２受容体アゴニスト |
| TW202502342A (zh) | 2023-06-02 | 2025-01-16 | 日商武田藥品工業股份有限公司 | 食慾素２受體促效劑用於改善睡眠期間之呼吸功能的用途 |
| AU2024361979A1 (en) * | 2023-10-20 | 2026-03-05 | Alkermes, Inc. | Compound for use in treating narcolepsy |
| WO2025096445A1 (en) | 2023-10-30 | 2025-05-08 | Alkermes, Inc. | Synthesis of intermediates for the preparation of macrocyclic compounds |
| CN122374291A (zh) | 2023-12-12 | 2026-07-10 | 爱杜西亚药品有限公司 | 作为食欲素受体调节剂的芳基砜及砜酮衍生物 |
| WO2025132542A1 (en) | 2023-12-19 | 2025-06-26 | Idorsia Pharmaceuticals Ltd | Macrocyclic orexin agonists |
| TW202547576A (zh) * | 2024-04-04 | 2025-12-16 | 日商橘生藥品工業股份有限公司 | 取代磺醯胺巨環狀化合物 |
| WO2025224168A1 (en) | 2024-04-24 | 2025-10-30 | Idorsia Pharmaceuticals Ltd | Aryl sulfone and sulfanone derivatives as orexin receptor modulators |
| WO2025229493A1 (en) | 2024-04-29 | 2025-11-06 | Takeda Pharmaceutical Company Limited | Dosing of orexin type 2 receptor agonists |
| WO2026017128A1 (zh) * | 2024-07-17 | 2026-01-22 | 江苏恩华药业股份有限公司 | 作为食欲素受体激动剂的环烯烃衍生物及其组合物和用途 |
| US20260144795A1 (en) | 2024-11-27 | 2026-05-28 | H. Lundbeck A/S | Spiromacrocyclic orexin 2 receptor agonists |
Family Cites Families (113)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE59010908D1 (de) | 1989-09-12 | 2000-08-10 | Hoffmann La Roche | TNF-bindende Proteine |
| US5635599A (en) | 1994-04-08 | 1997-06-03 | The United States Of America As Represented By The Department Of Health And Human Services | Fusion proteins comprising circularly permuted ligands |
| WO1999023114A1 (en) | 1997-10-31 | 1999-05-14 | Biomira Inc. | Muc-1 derivatives and their use in treating cancer-associated muc-1 mucin-induced immunosuppression |
| AU2903999A (en) | 1998-03-12 | 1999-09-27 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines |
| CA2324205A1 (en) | 1998-04-03 | 1999-10-14 | University Of Washington | Circularly permuted biotin binding proteins |
| EP1151012A4 (en) | 1998-11-19 | 2003-01-08 | Smithkline Beecham Corp | ANTAGONIST ANTIBODIES OF RHAMM |
| US6428985B1 (en) | 1998-12-02 | 2002-08-06 | The Regents Of The University Of Michigan | Immunosuppressive structural definition of IL-10 |
| ATE407697T1 (de) | 1999-07-13 | 2008-09-15 | Bolder Biotechnology Inc | Erythropoietin immunglobulin fusionsproteine |
| US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
| CA2391080A1 (en) | 1999-11-12 | 2001-05-25 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Erythropoietin forms with improved properties |
| AU2001231532A1 (en) | 2000-02-11 | 2001-08-20 | Maxygen Aps | Improved interleukin 10 |
| JP2003530384A (ja) | 2000-04-06 | 2003-10-14 | メルク フロスト カナダ アンド カンパニー | カテプシンシステインプロテアーゼ阻害薬 |
| SI1724284T1 (sl) | 2000-12-07 | 2009-12-31 | Lilly Co Eli | Glp-1 fuzijski proteini |
| HUP0400698A3 (en) | 2001-02-06 | 2006-01-30 | Merck Patent Gmbh | Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity |
| WO2003010201A2 (en) | 2001-07-20 | 2003-02-06 | Absorber, Ab | Blood group antigen fusion polypeptides and methods of use thereof |
| US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| US7638323B2 (en) | 2002-08-09 | 2009-12-29 | Recopharma Ab | Fusion proteins and methods of producing same |
| WO2004044006A1 (en) | 2002-11-14 | 2004-05-27 | Maxygen, Inc. | Conjugates of interleukin-10 and polymers |
| WO2004060911A2 (en) | 2002-12-30 | 2004-07-22 | Amgen Inc. | Combination therapy with co-stimulatory factors |
| SI1624891T2 (sl) | 2003-05-06 | 2013-09-30 | Biogen Idec Hemophilia Inc. | Strjevalni faktor-FC himerni proteini za zdravljenje hemofilije |
| US7696322B2 (en) | 2003-07-28 | 2010-04-13 | Catalent Pharma Solutions, Inc. | Fusion antibodies |
| US20150071948A1 (en) | 2003-09-26 | 2015-03-12 | Gregory Alan Lazar | Novel immunoglobulin variants |
| WO2005034863A2 (en) | 2003-10-03 | 2005-04-21 | Jarikuma Corporation | Countermeasures against malaria |
| WO2005042573A1 (en) | 2003-10-24 | 2005-05-12 | Dana-Farber Cancer Institute, Inc. | Modulation of the interaction of muc1 with muc1 ligands |
| US8454963B2 (en) | 2003-11-13 | 2013-06-04 | Musc Foundation For Research Development | Tissue targeted complement modulators |
| US7576183B2 (en) | 2003-12-24 | 2009-08-18 | Los Alamos National Security, Llc | Structure-based receptor MIMICS targeted against bacterial superantigen toxins |
| US7851463B2 (en) | 2004-10-14 | 2010-12-14 | Abbott Gmbh & Co. Kg | Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor |
| CA2588449A1 (en) | 2004-11-24 | 2006-06-01 | Therakine Corporation | An implant for intraocular drug delivery |
| KR20080013853A (ko) | 2005-02-23 | 2008-02-13 | 사이케노믹스, 인코퍼레이티드 | 복수매개물질 도파민 수송체 저해물질 및 이와 관련된 용도 |
| US7829679B2 (en) | 2005-08-12 | 2010-11-09 | Riken | Mucin-type glycoprotein and use thereof |
| JPWO2007063907A1 (ja) | 2005-11-30 | 2009-05-07 | 塩野義製薬株式会社 | ペプチド糖鎖付加体およびそれを有効成分とする医薬 |
| ATE437889T1 (de) | 2005-12-02 | 2009-08-15 | Apceth Gmbh & Co Kg | Chemokin-mucin fusionsproteine mit einer gpi- ankerdomäne und deren verwendung als tumor-immun- adjuvanzien oder in der geweberegeneration |
| WO2008140595A2 (en) | 2006-12-01 | 2008-11-20 | President And Fellows Of Harvard College | Synthetic trivalent haptens, complexes thereof, and uses therefor |
| WO2008133928A2 (en) | 2007-04-27 | 2008-11-06 | The Gi Company, Inc. | Mucin glycoproteins and their use for treatment of epithelial lesions and mucin dependent disorders |
| CA2695374A1 (en) | 2007-08-15 | 2009-02-19 | Amunix, Inc. | Compositions and methods for modifying properties of biologically active polypeptides |
| US8258163B2 (en) | 2008-06-04 | 2012-09-04 | Board Of Regents, The University Of Texas System | Small-molecule agonists for type-2 orexin receptor |
| BRPI0914889A2 (pt) | 2008-06-17 | 2015-11-24 | Otsuka Chemical Co Ltd | peptídeo glp-1 adicionado de cadeia oligossacarídica |
| RU2518471C2 (ru) * | 2008-08-14 | 2014-06-10 | Тиботек Фармасьютикалз | Макроциклические индольные производные, применимые в качестве ингибиторов вируса гепатита с |
| JP2012525415A (ja) | 2009-05-01 | 2012-10-22 | オプソテツク・コーポレイシヨン | 眼科疾患を処置または予防するための方法 |
| AU2010264095B2 (en) | 2009-06-26 | 2013-07-11 | Biogen Ma Inc. | Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof |
| KR20120107122A (ko) | 2009-12-22 | 2012-09-28 | 노파르티스 아게 | 치료법에서 사용하기 위한 ４가 ｃｄ４７―항체 불변 영역 융합 단백질 |
| US20130089554A1 (en) | 2009-12-29 | 2013-04-11 | Emergent Product Development Seattle, Llc | RON Binding Constructs and Methods of Use Thereof |
| AR080993A1 (es) | 2010-04-02 | 2012-05-30 | Hanmi Holdings Co Ltd | Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina |
| CN101962413B (zh) | 2010-09-21 | 2013-03-13 | 中国科学技术大学 | 具有透皮能力和白细胞介素-10活性的融合蛋白及其编码基因与应用 |
| KR101333958B1 (ko) | 2010-10-20 | 2013-11-27 | 주식회사 한독 | 인간 인터루킨-1 수용체 길항제-하이브리드 Ｆｃ 융합단백질 |
| EP2457579A1 (en) | 2010-11-26 | 2012-05-30 | Technische Universität Dresden | Covalently linked interleukin -10 |
| TWI622597B (zh) | 2011-03-28 | 2018-05-01 | 賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| US9527807B2 (en) | 2011-04-05 | 2016-12-27 | Takeda Pharmaceutical Company Limited | Sulfonamide derivative and use thereof |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| US11492383B2 (en) | 2011-06-24 | 2022-11-08 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
| LT2748201T (lt) | 2011-08-23 | 2018-02-26 | Roche Glycart Ag | Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė |
| EP2836485B1 (en) | 2012-03-17 | 2018-01-10 | Polyphor Ag | Conformationally constrained, fully synthetic macrocyclic compounds |
| US9062120B2 (en) | 2012-05-02 | 2015-06-23 | Janssen Biotech, Inc. | Binding proteins having tethered light chains |
| EP2851429B1 (en) | 2012-05-18 | 2019-07-24 | Adda Biotech Inc. | Protein and protein conjugate for diabetes treatment, and applications thereof |
| US9156897B2 (en) | 2012-06-08 | 2015-10-13 | Alkermes, Inc. | Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide |
| CN104640561A (zh) | 2012-07-23 | 2015-05-20 | 酵活有限公司 | 包含轻链和重链的选择性配对的免疫球蛋白构建体 |
| US9346872B2 (en) | 2012-08-08 | 2016-05-24 | Roche Glycart Ag | Interleukin-10 fusion proteins |
| WO2014151910A1 (en) | 2013-03-15 | 2014-09-25 | Amgen Inc. | Heterodimeric bispecific antibodies |
| JP2016526014A (ja) | 2013-04-24 | 2016-09-01 | アルモ・バイオサイエンシーズ・インコーポレイテッド | インターロイキン−１０組成物及びその使用 |
| WO2014198880A1 (en) | 2013-06-14 | 2014-12-18 | Ferrer Internacional, S.A. | 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity |
| EP3027647A4 (en) | 2013-07-31 | 2017-01-04 | Amgen Inc. | Stabilization of fc-containing polypeptides |
| US20160250224A1 (en) | 2013-09-24 | 2016-09-01 | The Board Of Regents Of The University Of Texas System | Orexin-control of bone formation and loss |
| WO2015073707A1 (en) | 2013-11-15 | 2015-05-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating heart failure with agonists of hypocretin receptor 2 |
| SG11201604639YA (en) | 2013-12-12 | 2016-07-28 | Univ Tsukuba | Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof |
| BR112016016658A2 (pt) | 2014-02-06 | 2018-01-23 | F. Hoffmann-La Roche Ag | proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão |
| JP6552117B2 (ja) | 2014-03-28 | 2019-07-31 | 国立大学法人 筑波大学 | 敗血症の予防治療剤 |
| JP6715239B2 (ja) | 2014-09-11 | 2020-07-01 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換２−アザ二環式化合物及びオレキシン受容体調節因子としてのその使用 |
| CN104403004B (zh) | 2014-11-24 | 2017-10-13 | 苏州丁孚靶点生物技术有限公司 | 抗体‑干扰素异二聚体的制备和用途 |
| EP3233920B1 (en) | 2014-12-19 | 2020-08-26 | Alkermes, Inc. | Single chain fc fusion proteins |
| WO2016101119A1 (en) * | 2014-12-23 | 2016-06-30 | Merck Sharp & Dohme Corp. | Fused heteroaryl derivatives as orexin receptor antagonists |
| WO2016133160A1 (ja) | 2015-02-19 | 2016-08-25 | 国立大学法人筑波大学 | スルホンアミド誘導体またはその薬学的に許容される酸付加塩 |
| CA2989146A1 (en) | 2015-06-12 | 2016-12-15 | Board Of Regents, The University Of Texas System | Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof |
| DK3310784T3 (da) * | 2015-06-17 | 2020-11-09 | Pfizer | Tricykliske forbindelser og deres anvendelse som phosphodiesterasehæmmere |
| WO2017035354A1 (en) * | 2015-08-26 | 2017-03-02 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to ntrk |
| US10377770B2 (en) * | 2015-12-18 | 2019-08-13 | Novartis Ag | Tricyclic compounds and compositions as kinase inhibitors |
| SG11201806429PA (en) | 2016-02-04 | 2018-08-30 | Takeda Pharmaceuticals Co | Substituted piperidine compound and use thereof |
| US11291721B2 (en) | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| WO2018005226A2 (en) | 2016-06-22 | 2018-01-04 | Alkermes, Inc. | Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties |
| JP6957598B2 (ja) | 2017-03-08 | 2021-11-02 | 武田薬品工業株式会社 | 置換ピロリジン化合物およびその用途 |
| JP7012703B2 (ja) | 2017-03-08 | 2022-02-14 | 武田薬品工業株式会社 | 置換ピロリジン化合物およびその用途 |
| US10428023B2 (en) | 2017-08-03 | 2019-10-01 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| US11319286B2 (en) | 2017-08-03 | 2022-05-03 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
| CN111132975B (zh) | 2017-09-28 | 2023-05-23 | 勃林格殷格翰国际有限公司 | N-(2,2-二氟乙基)-n-[(嘧啶基氨基)丙基]芳基甲酰胺 |
| JP7170996B2 (ja) | 2017-12-12 | 2022-11-15 | 国立大学法人 筑波大学 | スルホンアミド誘導体またはその薬学的に許容される酸付加塩 |
| WO2019191327A1 (en) | 2018-03-27 | 2019-10-03 | Board Of Regents, The University Of Texas System | Ox2r compounds |
| US11655241B2 (en) | 2018-06-29 | 2023-05-23 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| EP3816154B1 (en) | 2018-06-29 | 2025-04-23 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
| JP7408569B2 (ja) | 2018-12-12 | 2024-01-05 | 武田薬品工業株式会社 | 複素環化合物 |
| JP7379374B2 (ja) | 2018-12-12 | 2023-11-14 | 武田薬品工業株式会社 | 複素環化合物 |
| PE20211700A1 (es) | 2019-01-31 | 2021-09-01 | Takeda Pharmaceuticals Co | Compuesto heterociclico y su uso |
| US11098029B2 (en) | 2019-02-13 | 2021-08-24 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
| WO2020167701A1 (en) | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | Pyrrolidine orexin receptor agonists |
| EP4010314B1 (en) | 2019-08-08 | 2024-02-28 | Merck Sharp & Dohme LLC | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
| JP2022547604A (ja) | 2019-09-13 | 2022-11-14 | 武田薬品工業株式会社 | 過度の眠気の治療のためのオレキシン２受容体アゴニストの使用 |
| KR20260083444A (ko) | 2019-11-25 | 2026-06-05 | 알케르메스,인코포레이티드 | 치환된 마크로사이클릭 화합물 및 관련 치료 방법 |
| US11352357B2 (en) | 2019-11-27 | 2022-06-07 | Sumitomo Dainippon Pharma Co., Ltd. | Cycloalkylurea derivative |
| WO2021106975A1 (ja) | 2019-11-27 | 2021-06-03 | 武田薬品工業株式会社 | 複素環化合物 |
| CA3167050A1 (en) | 2020-01-10 | 2021-07-15 | Takeda Pharmaceutical Company Limited | A method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof with an inhibitor of cytochrome p450 |
| CN119235864A (zh) | 2020-07-17 | 2025-01-03 | 卫材R&D管理有限公司 | 取代的哌啶化合物及其用途 |
| WO2022040058A1 (en) | 2020-08-18 | 2022-02-24 | Merck Sharp & Dohme Corp. | Cyclopentapyrrole orexin receptor agonists |
| US20230365533A1 (en) | 2020-08-18 | 2023-11-16 | Merck Sharp & Dohme Llc | Bicycloheptane pyrrolidine orexin receptor agonists |
| US12503475B2 (en) | 2020-09-03 | 2025-12-23 | Centessa Pharmaceuticals (Uk) Limited | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists |
| CN116635393A (zh) | 2020-09-03 | 2023-08-22 | 欧瑞夏治疗有限公司 | 中环或大环苄基取代的杂环衍生物及其作为食欲素-2受体激动剂的用途 |
| JP2022064180A (ja) | 2020-10-13 | 2022-04-25 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2022094012A1 (en) | 2020-11-02 | 2022-05-05 | Merck Sharp & Dohme Corp. | Macrocyclic urea orexin receptor agonists |
| EP4247801A4 (en) * | 2020-11-23 | 2024-10-30 | Merck Sharp & Dohme LLC | 3-AMINO PYRROLIDINE AND MACROCYCLIC PIPERIDINE OREXIN RECEPTOR AGONISTS |
| US12552767B2 (en) | 2020-12-03 | 2026-02-17 | Merck Sharp & Dohme Llc | 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists |
| US12692262B2 (en) | 2020-12-16 | 2026-07-28 | Merck Sharp & Dohme Llc | Substituted ureas as orexin receptor agonists |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| US12006330B2 (en) | 2020-12-21 | 2024-06-11 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| JP7860139B2 (ja) | 2021-03-03 | 2026-05-15 | リサーチ トライアングル インスティテュート | オレキシン受容体アゴニストとしてのアリールスルホンアミド |
| WO2022207935A1 (en) | 2021-04-02 | 2022-10-06 | Orexia Therapeutics Limited | 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists |
| MX2023012971A (es) | 2021-05-03 | 2024-01-16 | Jazz Pharmaceuticals Ireland Ltd | Agonistas del receptor de orexina y sus usos. |
-
2020
- 2020-11-25 KR KR1020267016156A patent/KR20260083444A/ko active Pending
- 2020-11-25 IL IL293240A patent/IL293240B2/en unknown
- 2020-11-25 SM SM20250340T patent/SMT202500340T1/it unknown
- 2020-11-25 SI SI202030661T patent/SI4065585T1/sl unknown
- 2020-11-25 WO PCT/US2020/062320 patent/WO2021108628A1/en not_active Ceased
- 2020-11-25 EP EP25195771.8A patent/EP4628167A3/en active Pending
- 2020-11-25 HU HUE20828463A patent/HUE073461T2/hu unknown
- 2020-11-25 BR BR112022009938A patent/BR112022009938A2/pt unknown
- 2020-11-25 IL IL320038A patent/IL320038A/en unknown
- 2020-11-25 AU AU2020394444A patent/AU2020394444B2/en active Active
- 2020-11-25 PT PT208284638T patent/PT4065585T/pt unknown
- 2020-11-25 US US17/104,993 patent/US11542276B2/en active Active
- 2020-11-25 FI FIEP20828463.8T patent/FI4065585T3/fi active
- 2020-11-25 JP JP2022529454A patent/JP7787812B2/ja active Active
- 2020-11-25 LT LTEPPCT/US2020/062320T patent/LT4065585T/lt unknown
- 2020-11-25 EP EP20828463.8A patent/EP4065585B1/en active Active
- 2020-11-25 ES ES20828463T patent/ES3041424T3/es active Active
- 2020-11-25 MA MA57908A patent/MA57908B1/fr unknown
- 2020-11-25 MD MDE20221089T patent/MD4065585T2/ro unknown
- 2020-11-25 MX MX2022006206A patent/MX2022006206A/es unknown
- 2020-11-25 CN CN202080081320.8A patent/CN114761412B/zh active Active
- 2020-11-25 RS RS20250911A patent/RS67202B1/sr unknown
- 2020-11-25 HR HRP20251156TT patent/HRP20251156T1/hr unknown
- 2020-11-25 KR KR1020227021501A patent/KR102969640B1/ko active Active
- 2020-11-25 DK DK20828463.8T patent/DK4065585T3/da active
-
2022
- 2022-05-23 SA SA522432691A patent/SA522432691B1/ar unknown
- 2022-06-10 ZA ZA2022/06482A patent/ZA202206482B/en unknown
- 2022-11-22 US US17/991,899 patent/US12054495B2/en active Active
-
2024
- 2024-06-17 US US18/745,031 patent/US20250092063A1/en active Pending
-
2025
- 2025-05-07 AU AU2025203295A patent/AU2025203295B2/en active Active
- 2025-08-27 JP JP2025141156A patent/JP2025186272A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SMT202500340T1 (it) | Composti macrociclici sostituiti e metodi di trattamento correlati | |
| IL287909A (en) | Macrocyclic adsorbents and methods of using them | |
| IL292810A (en) | Therapeutic compounds and methods of use | |
| GB201804514D0 (en) | Treatment of pyroptosis | |
| AU2019383310B2 (en) | Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers | |
| PT4076461T (pt) | Lumateperona para utilização no tratamento da esquizofrenia | |
| IL286697A (en) | Neurogulin-4 compounds and methods of use | |
| IL290983A (en) | Treatment methods | |
| IL299163A (en) | Macrocyclic compounds and methods of using them | |
| GB2589398B (en) | Compounds and methods of use | |
| GB201804515D0 (en) | Treatment of necroptosis | |
| GB201916428D0 (en) | Treatment of hydro-carbon-contaminated materials | |
| IL287250A (en) | treatment method | |
| GB201907305D0 (en) | Treatment of conditions | |
| GB201918853D0 (en) | Methods of treatment | |
| GB201810923D0 (en) | Compositions and method of treatment | |
| IL268111A (en) | Methods of treating pain | |
| GB201911056D0 (en) | Treatment of ADD/ADHD | |
| GB201900942D0 (en) | Methods of treatment | |
| GB202118007D0 (en) | Methods of treatment | |
| GB202118006D0 (en) | Methods of treatment | |
| GB202118011D0 (en) | Methods of treatment | |
| GB202108242D0 (en) | Methods of treatment | |
| GB202108245D0 (en) | Methods of treatment | |
| GB201908573D0 (en) | Compounds and methods of use |